<SEC-DOCUMENT>0001837607-25-000013.txt : 20250224
<SEC-HEADER>0001837607-25-000013.hdr.sgml : 20250224
<ACCEPTANCE-DATETIME>20250224140128
ACCESSION NUMBER:		0001837607-25-000013
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250224
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250224
DATE AS OF CHANGE:		20250224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEON Biopharma, Inc.
		CENTRAL INDEX KEY:			0001837607
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				853940478
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40021
		FILM NUMBER:		25655925

	BUSINESS ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		(949) 354-6499

	MAIL ADDRESS:	
		STREET 1:		5 PARK PLAZA
		STREET 2:		SUITE 1750
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Priveterra Acquisition Corp.
		DATE OF NAME CHANGE:	20201222
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aeon-20250224x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 2/24/2025 6:32:41 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: e79b0eff-d1b8-4e33-a8a6-827813fad5c4 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:aeon="http://www.aeonbiopharma.com/20250224" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>AEON Biopharma,&#160;Inc._February 24, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityCentralIndexKey" id="Tc_d4URmFxzd0CW7KBq7rTIyg_2_1">0001837607</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:AmendmentFlag" id="Tc_JvA4Xv-c20-urp5JrcZchw_3_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:CurrentFiscalYearEndDate" id="Tc_Th76yLB1tE-atk6m6_2BFA_4_1">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="aeon-20250224.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001837607</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_04aaaa2d_783c_4b69_a792_c6a320d8e17d"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:DocumentType" id="Narr_luq_sqoW8UK-YKSylB2USw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_bOHZwPT040iTVr6oTonuMQ"><b style="font-weight:bold;">February 24, 2025</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityRegistrantName" id="Narr_YUFzgb_03EqMz88y1nzE9g"><b style="font-weight:bold;">AEON Biopharma,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a3df5546_1afe_49c6_8b45_dda32ca530b0"></a><a id="Tc_rQdgBIclFk2eJzfVSksnaQ_2_0"></a><a id="Tc_FyOghCO5ZEWU5zggxz2Yeg_2_2"></a><a id="Tc_CcWFmgaj3kuzQDW6p0A6ww_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:34.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:25.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:36.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:34.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_pdtfa48Yv02OZByPVadCtg_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityFileNumber" id="Tc_lv7skw-AZUmkSFknN3nuyQ_1_2"><b style="font-size:8pt;font-weight:bold;">001-40021</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityTaxIdentificationNumber" id="Tc_NyZV33p9PkSzA3pdYpUqoQ_1_4"><b style="font-size:8pt;font-weight:bold;">85-3940478</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:34.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:25.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:36.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification Number)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityAddressAddressLine1" id="Narr_W721m699oUWx6g91P9-U7g"><b style="font-size:8pt;font-weight:bold;">5 Park Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityAddressAddressLine2" id="Narr_94hTkhqBGEaASVJZB3-hQw"><b style="font-size:8pt;font-weight:bold;">Suite&#160;1750</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityAddressCityOrTown" id="Narr_VtwN53k6BUO55IEJamtW2A"><b style="font-size:8pt;font-weight:bold;">Irvine</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityAddressStateOrProvince" id="Narr_WgV_JsjS00q5Z2uvCFNLhg"><b style="font-size:8pt;font-weight:bold;">CA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:EntityAddressPostalZipCode" id="Narr_ecAsPVfPE0SNWN1ycH7zUw"><b style="font-size:8pt;font-weight:bold;">92614</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:CityAreaCode" id="Narr_3glHtr-NbECZPQ9Gp67okw"><b style="font-size:8pt;font-weight:bold;">949</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:LocalPhoneNumber" id="Narr_Jd1HSGU8WUeQx6DD8in0sQ"><b style="font-size:8pt;font-weight:bold;">354-6499</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_G5zoCP8ZeEqXPqm20X-LPA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_RY29oCgDlEaPP21FzOujbw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_XYSKmgJrREu2UFnAC0ydxA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_lIXo2yR9jEiMJZx2UTJ-Jg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><span style="font-size:8pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e9e601d6_be32_4696_b167_2f5795049325"></a><a id="Tc_9gUUxcss8Uad2dfRrrdk5w_1_0"></a><a id="Tc_NTXenYEndUC5IEvISkpOQA_1_2"></a><a id="Tc_IOxnSKSQwk2FIBYWLQ39pg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:24.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:24.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:Security12bTitle" id="Tc_TmKBrq7_WECXCy2gwyHTfQ_2_0"><span style="font-size:8pt;">Class&#160;A Common Stock, $0.0001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" name="dei:TradingSymbol" id="Tc_WkVfeh34WkSBcBamLNoHug_2_2"><span style="font-size:8pt;">AEON</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_SH2yYDCZdkGDxBUVjEE5wQ_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_pFJEJDnzZU-XRMWb8KW-6Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_vnJLtn9weUmC6f13T3yd4A"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_12944964_f90c_402b_bc18_1289ebd9a304"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 3.03. Material Modification of Rights of Security Holders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0d3403c4_cc13_4c05_9f66_646e147a4618"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 5.03. Amendments to Articles of Incorporation or Bylaws.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Certificate of Amendment of Amended and Restated Certificate of Incorporation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">AEON Biopharma, Inc. (the &#8220;Company&#8221;) held a Special Meeting of Stockholders on February 24, 2025 (the &#8220;Special Meeting&#8221;) as described in the Company&#8217;s proxy statement for the Special Meeting, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on January 23, 2025 (the &#8220;Special Meeting Proxy&#8221;). During the Special Meeting, the Company&#8217;s shareholders voted to amend the Company&#8217;s Third Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), to increase the number of authorized shares of the Company&#8217;s common stock, par value $0.0001 (the &#8220;Common Stock&#8221;) from 500,000,000 to 1,040,000,000, as described in the Company&#8217;s Proxy Statement filed with the Securities and Exchange Commission on January 23, 2025. The amendment to the Certificate of Incorporation will be filed with the Secretary of State of the State of Delaware on February 25, 2025 and became effective on such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the Certificate of Incorporation does not purport to be complete and is qualified in its entirety by reference to the Certificate of Incorporation, a copy of which is included as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the Special Meeting, the Company&#8217;s stockholders approved a proposal granting the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) the discretion to amend the Company&#8217;s Certificate of Incorporation to effect a reverse stock split of the Common Stock, at a ratio of 1-for-5 to 1-for-150, with the ratio within such range to be determined at the discretion of the Board. Following the Special Meeting, the Board approved the filing of a Certificate of Amendment to the Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) to effect a reverse stock split at a final split ratio of 1-for-72 (the &#8220;Reverse Stock Split&#8221;). The Company intends to file the Charter Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split on February 25, 2025, to become effective at 12:01 a.m. Eastern Time on February 26, 2025 (the &#8220;Effective Date&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Split Adjustment; Treatment of Fractional Share</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result of the 1-for-72 Reverse Stock Split, each 72 pre-split shares of Common Stock outstanding will automatically combine into one new share of Common Stock without any action on the part of the holders, and the number of outstanding shares of Common Stock will be reduced from approximately 79.9 million shares (as of the date hereof) to approximately 1.1 million shares (subject to rounding of fractional shares, which will be rounded up to the nearest whole share). Proportional adjustments will also be made to the number of shares of Common Stock issuable upon exercise or conversion of the Company&#8217;s outstanding equity awards and warrants, as well as the applicable exercise price, except in cases where the applicable agreement provides otherwise. The Reverse Stock Split will affect all of the Company&#8217;s stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in the Company.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No fractional shares will be issued in connection with the Reverse Stock Split. In lieu of fractional shares, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following the effective time of the Reverse Stock Split (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall instead receive a number of shares rounded up to the nearest whole share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Trading Symbol; New CUSIP</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">After the Reverse Stock Split, the trading symbol for the Common Stock will continue to be &#8220;AEON&#8221;. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 00791X 209. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Certificate of Amendment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The description of the Charter Amendment set forth above does not purport to be complete and is qualified in its entirety by the full text of the form of Charter Amendment that is included in the amendment to the Certificate of Incorporation, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3f4576e9_6aa9_4b6b_8223_6a0004011b41"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 5.07. Submission of Matters to a Vote of Security Holders.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">At the Special Meeting, the stockholders of the Company voted on four proposals as further described in the Special Meeting Proxy. The final results for each proposal voted on by the stockholders at the Special Meeting, as certified by the Company&#8217;s inspector of elections, are set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposal 1</span>: The stockholders of the Company approved an amendment to our certificate of incorporation to increase the number of authorized shares of our Common Stock from 500,000,000 to 1,040,000,000 (the &#8220;Authorizes Share Increase Proposal&#8221;). The voting results with respect to this proposal were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Against</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Abstain</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker Non-Vote</b></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">31,264,128</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">4,878,082</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">43,064</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">-</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposal 2</span>: The stockholders of the Company granted discretionary authority to our board of directors to (i) amend our certificate of incorporation to combine outstanding shares of our Common Stock into a lesser number of outstanding shares, or a &#8220;reverse stock split,&#8221; at a specific ratio within a range of one-for-five (1-for-5) to a maximum of a one-for-one hundred fifty (1-for-150), with the exact ratio to be determined by our board of directors in its sole discretion; and (ii) effect the reverse stock split, if at all, within one year of the date the proposal is approved by stockholders (the &#8220;Reverse Stock Split Proposal&#8221;). The voting results for this proposal were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Against</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Abstain</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker Non-Vote</b></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">32,605,697</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">3,560,400</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">19,177</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">-</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposal 3</span>: The stockholders of the Company authorized, for purposes of complying with NYSE American listing rule 711.05, the issuance of Warrants, shares of Common Stock underlying the Warrants and certain provisions of the Warrants, issued in connection with an offering and sale of securities of the Company that was consummated on January 7, 2025 (the &#8220;Issuance Proposal&#8221;). The voting results for this proposal were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Against</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Abstain</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker Non-Vote</b></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">20,088,258</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">1,255,440</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">8,262,706</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">6,578,870</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposal 4</span>: The stockholders of the Company approved one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Authorized Share Increase Proposal, Reverse Stock Split Proposal, or the Issuance Proposal if there are not sufficient votes at the Special Meeting to approve and adopt the Reverse Stock Split Proposal, the Authorized Share Increase Proposal or the Issuance Proposal (the &#8220;Adjournment Proposal&#8221;). The voting results for this proposal were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Against</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Abstain</b></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Broker Non-Vote</b></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">31,394,646</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">4,769,915</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">20,713</p></td><td style="vertical-align:top;width:25%;background:#bdd7ee;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">-</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5e14fc44_9023_45f8_9b89_ab536623476d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 7.01. Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, on February 24, 2025, the Company issued a press release relating to the Reverse Stock Split described in this Current Report on Form 8-K. A copy of the press release attached as Exhibit 99.1 to this report is being furnished and incorporated by reference into this Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this Item 7.01 and the accompanying exhibit shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_478471ae_43bf_4db3_bf0a_44a8dc09cd8f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">(d) Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:88.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:88.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:88.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:1.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aeon-20250224xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of AEON Biopharma, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aeon-20250224xex99.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated February 24, 2025</span></a>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7a34f1dd_1d51_47d4_af73_97738705d089"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">AEON Biopharma,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: February 24, 2025</p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marc Forth</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marc Forth</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>aeon-20250224xex3d1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 06:32:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:7.06%;padding-right:7.06%;position:relative;"><div style="margin-top:22.3pt;min-height:49.7pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt -36pt;"><b style="font-weight:bold;">Exhibit 3.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:8pt 0pt 8pt 0pt;"> <b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">AEON BIOPHARMA, INC.,</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">a Delaware Corporation</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">AEON Biopharma, Inc. (the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Corporation</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FIRST:</u><font style="font-family:'Arial','Helvetica','sans-serif';"> That the undersigned is the duly elected and acting Chief Executive Officer of the Corporation.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECOND:</u><font style="font-family:'Arial','Helvetica','sans-serif';"> That, pursuant to Section 242 of the Delaware General Corporation Law (the </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8220;DGCL&#8221;),</b><font style="font-family:'Arial','Helvetica','sans-serif';"> the first paragraph of Article Fourth of the Third Amended and Restated Certificate of Incorporation of the Corporation is hereby amended to read in its entirety as follows:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8220;FOURTH: </b><font style="font-family:'Arial','Helvetica','sans-serif';">The total number of shares of all classes of capital stock that the Corporation is authorized to issue is 1,041,000,000 shares, consisting of (i) 1,040,000,000 shares of common stock, par value $0.0001 per share (the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Common Stock</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share (the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Preferred Stock</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;).</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">&#8221;</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Upon the filing and effectiveness (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Time</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;) pursuant to the General Corporation Law of the State of Delaware of this Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Corporation, each seventy two (72) shares of Common Stock either issued and outstanding or held by the Corporation in treasury stock immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of Common Stock (the &#8220;</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split</u><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">No fractional shares shall be issued in connection with the Reverse Stock Split. Instead, holders who would be entitled to receive fractional shares of Common Stock because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be issued an additional fraction of a share of Common Stock to round up to the next whole post-Reverse Stock Split share of Common Stock. For those stockholders who hold shares with a brokerage firm, the Company intends to round up fractional shares at the participant level. No cash will be paid in lieu of fractional shares.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">THIRD:</u><font style="font-family:'Arial','Helvetica','sans-serif';"> That the foregoing Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of the Corporation has been duly adopted and approved by the Board of Directors and stockholders of the Corporation in accordance with the applicable provisions of Sections 228 and 242 of the Delaware General Corporation Law.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">IN WITNESS WHEREOF, the undersigned hereby further declares and certifies under penalty of perjury that the facts set forth in the foregoing certificate are true and correct to the knowledge of the undersigned, and that this certificate is the act and deed of the undersigned.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Executed on this 24</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:8.25pt;vertical-align:top;">th</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> day of February, 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;text-indent:18pt;margin:8pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:81.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.23%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:11.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:81.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Marc Forth&#160;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:2.23%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:11.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:81.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Marc Forth</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:2.23%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:11.57%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:81.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Chief Executive Officer</font></p></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td><td style="vertical-align:top;width:2.23%;margin:0pt;padding:0pt 0pt 2.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:11pt;"><a name="TrailerStart"></a></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:1.28;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:7.06%;margin-right:7.06%;margin-top:30pt;page-break-after:avoid;width:85.88%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>aeon-20250224xex99.htm
<DESCRIPTION>EX-99
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 2/24/2025 06:32:39 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:7.06%;padding-right:7.06%;position:relative;"><div style="margin-top:22.3pt;min-height:49.7pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:24.15pt;left:-0.29%;position:absolute;top:-23.8pt;width:99.08pt;z-index:251658240;"><div style="height:24.15pt;left:0pt;padding-bottom:0pt;position:relative;width:99.08pt;"><img src="aeon-20250224xex99001.jpg" alt="Graphic" style="height:24.15pt;width:99.08pt;"></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt -36pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:-36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:44.52%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">PRESS RELEASE</b></font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:30.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">AEON Biopharma, Inc. Announces Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">IRVINE, Calif., February 24, 2025</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> -- AEON Biopharma, Inc. (NYSE: AEON) (the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that the Company&#8217;s Board of Directors approved a 1-for-72 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), to increase the selling price of the Company&#8217;s Common Stock in order to maintain compliance with the requirements and policies of the NYSE American LLC (&#8220;the &#8220;NYSE American&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on February 26, 2025, and the Company&#39;s Common Stock will open for trading on the NYSE American on February 26, 2025, on a post-split basis, under the existing ticker symbol &quot;AEON&quot; but with a new CUSIP number 00791X 209.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">At the Company&#8217;s Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;) held on February 24, 2025, the Company&#8217;s stockholders approved a proposal to amend the Company&#8217;s certificate of incorporation to effect a reverse stock split of its Common Stock at a ratio of between 1-for-5 to 1-for-150, with the ratio within such range to be determined at the discretion of the Company&#8217;s Board. Following the Special Meeting, the Board approved a final split ratio of 1-for-72. Following the Reverse Stock Split, the ownership percentage of each stockholder will remain unchanged, other than with respect to fractional shares. No fractional shares will be issued in connection with the Reverse Stock Split, with any fractional shares instead being rounded up to the nearest whole share.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">Additional details regarding the Company&#8217;s Reverse Stock Split can be found in the Current Report on Form 8-K filed on February 24, 2025 with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">About AEON Biopharma</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit </font><font style="font-family:'Calibri','Helvetica','sans-serif';">www.aeonbiopharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:12pt;">.</font><font style="font-size:12pt;"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements</b><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">The foregoing material may contain &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company&#8217;s product development and business prospects, and can be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying </i></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:11pt;"><a name="TrailerStart"></a></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:1.28;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:7.06%;margin-right:7.06%;margin-top:30pt;page-break-after:always;width:85.88%;border-width:0;"><div style="max-width:100%;padding-left:7.06%;padding-right:7.06%;position:relative;"><div style="margin-top:22.3pt;min-height:49.7pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:24.15pt;left:-0.29%;position:absolute;top:-23.8pt;width:99.08pt;z-index:251658240;"><div style="height:24.15pt;left:0pt;padding-bottom:0pt;position:relative;width:99.08pt;"><img src="aeon-20250224xex99001.jpg" alt="Graphic" style="height:24.15pt;width:99.08pt;"></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt -36pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:-36pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:44.52%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">PRESS RELEASE</b></font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:30.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON&#8217;s future capital requirements; (iii) AEON&#8217;s ability to raise financing in the future; (iv) AEON&#8217;s ability to continue to meet continued stock exchange listing standards; (v) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vi) the Company&#8217;s ability to present a Plan that will be accepted by NYSE Regulation; and (vii) other risks and uncertainties set forth in the section entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in the Company&#8217;s filings with the SEC, which are available on the SEC&#8217;s website at </i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">www.sec.gov</i><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:14pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contacts </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">Investor Contact: </b><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">Corey Davis, Ph.D. </font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">LifeSci Advisors </font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">+1 212 915 2577 </font><font style="font-family:'Calibri','Helvetica','sans-serif';"><br></font><font style="font-family:'Calibri','Helvetica','sans-serif';">cdavis@lifesciadvisors.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:14pt 0pt 8pt 0pt;">Source: AEON Biopharma</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-size:11pt;"><a name="TrailerStart"></a></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:8pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;line-height:1.28;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:7.06%;margin-right:7.06%;margin-top:30pt;page-break-after:avoid;width:85.88%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>aeon-20250224xex99001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aeon-20250224xex99001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Q ,<# 2(  A$! Q$!_\0
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M9KR;K%!*PY4D?>91@8' QU[5Y)XHNM3U/Q3J$VI1R+JDMPWFQD$,KYQM ]N
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5!%%%%>C#X%Z'YYCO][J_XI?FS__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>aeon-20250224.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 6:32:47 PM-->
<!--Modified on: 2/24/2025 6:32:47 PM-->
<xsd:schema targetNamespace="http://www.aeonbiopharma.com/20250224" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:aeon="http://www.aeonbiopharma.com/20250224">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20250224_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20250224_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aeon-20250224_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>aeon-20250224_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 6:32:47 PM-->
<!--Modified on: 2/24/2025 6:32:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="aeon-20250224.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.aeonbiopharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>aeon-20250224_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 6:32:47 PM-->
<!--Modified on: 2/24/2025 6:32:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>aeon-20250224_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 2/24/2025 6:32:47 PM-->
<!--Modified on: 2/24/2025 6:32:47 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="aeon-20250224.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638760187674779913" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638760187674779913" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638760187674779913" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638760187674779913" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638760187674779913" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638760187674779913" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638760187674779913" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638760187674779913" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638760187674789923" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638760187674789923" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638760187674789923" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638760187674789923" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638760187674789923" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638760187674789923" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638760187674789923" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638760187674789923" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638760187674799915" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638760187674799915" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638760187674799915" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638760187674799915" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638760187674799915" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638760187674799915" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638760187674799915" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638760187674799915" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638760187674809909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638760187674809909" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638760187674809909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638760187674809909" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638760187674809909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638760187674809909" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638760187674809909" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638760187674809909" order="25" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46491153310736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 24,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AEON Biopharma,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3940478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Park Plaza<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite&#160;1750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">354-6499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEON<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MBR@[W#$*EFLN@/\W0NCW$_,BHW@/-?H74$L#!!0    ( "UP6%J?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( "UP6%H'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ +7!86F<I6S[O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ +7!86IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  M
M<%A:[KF[%ZD$  "3$@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ +7!86I^@&_"Q @  X@P   T
M         ( ![0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  M<%A:EXJ[
M',     3 @  "P              @ ')#P  7W)E;',O+G)E;'-02P$"% ,4
M    "  M<%A:'#AEZC\!   \ @  #P              @ &R$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ +7!86B0>FZ*M    ^ $  !H
M     ( !'A(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ +7!86F60>9(9 0  SP,  !,              ( ! Q,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  310

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aeon-20250224x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aeon-20250224.xsd</File>
    <File>aeon-20250224_def.xml</File>
    <File>aeon-20250224_lab.xml</File>
    <File>aeon-20250224_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="aeon-20250224x8k.htm">aeon-20250224x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aeon-20250224x8k.htm": {
   "nsprefix": "aeon",
   "nsuri": "http://www.aeonbiopharma.com/20250224",
   "dts": {
    "schema": {
     "local": [
      "aeon-20250224.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "aeon-20250224_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "aeon-20250224_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aeon-20250224_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aeon-20250224x8k.htm"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "report": {
    "R1": {
     "role": "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aeon-20250224x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aeon-20250224x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.aeonbiopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001837607-25-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001837607-25-000013-xbrl.zip
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M<73<>>KX6BR=OM)KLFU/_P=02P,$%     @ +7!86K:BLP;5!   /2L  !4
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M)7V&8(4%N\U:B%Y+6,E\W!I;_L<;CA>45-?8^Q MY&Y$6DE^W"+[3X8Y1V1
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M/IXY[X+H9/HB5L;.#D_#F&O>3[:>,=,;T9_"F),9 -R_IL^L1BHX"CF/>Y(
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MSSK,6S#MN)!]@8G]#H_?G.<-B=^0^ V)GYMN_BU(?,_3JF^>] ;+#X3EEND
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M$1D)HDL56N)7)1/P<"%3&4OG?X!TIKA!#N&AV[D8CH'[(A"4/V.%N(P8RA6
MI("UHD_3Y#L=&2;X&B#*P%DRL:KN(J"H9\KK'[?H:61,C&DDIN3SN,N4NS09
M,55FK,AK6X*XO,3<Z<D'* \8NH:>J;Q5B>4B^U(NC"'):\-_ ]:QF;H$GE(K
M"NHNDFOJJ:2RBAL%G1F@)-44O&]6(<-M0:D3RJ(F8!SJI>Z00;#"DG:E,$J6
M$T%XZO:=$@/*X6HC28Q-RR6NFFK=A(YJ5R0L,!S]!W,+_HR@KE4JI@8EJURZ
MTY:8Z1RA;&N#[W,=T'P^#Z@3ON0Z "<[H-SH>^V=!_<2K8_Z]MS[#B,BLHHY
MTI7V&V-NR3NPEG/9_SW&1?U%FL/=7X2;1$=5X0]'HL:&HP]@LQ1BIG)!(8C-
MO<JN1A7&285QOL2X2KI\N4/N8PIWXLO%*C_O'0]];5/+ZX815UW=TX,#MM;E
MZ.[EEM'+#' U#4DC5R#D::DH5%PDW<<JU8-)&</HDZ3^F*-%;$1J4")1NQHQ
M$]D^G!6*@ F<K['L<"C85$&)8E'>J@C2*B0^>9($OKYP]69MA4\GU#YV-)U7
MB'" .,,#N%S**U?LDFU-QP?PE*O A@2&@)D;&^>N\ 0PU0YB4UM^KZI'5%$U
MGY'3C8KF4S#P<<MC%$::M*;Y7(*O2&=;WF2)3)O/0I5H2+XQU!0DG]Q@,0?0
M2=Q\2@J+0*#\8U.E(D">CA\$U2P^.F*K@)2#">-<2.-$$,E;4KWYI"91MY/4
M98SB!=(JUU4<E939"%=C,FE$L!&=M2"(<63,V> ^136451:J4Y[)JE3+SF:H
MT)C)JD#UH984@[)5KZ&$-+/@=K1*#6@4K9*7X<>J_I:^NP4!K,YOW2#J1G/
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M?^*+*0?4'E#PLS+W-S^X+)99!JRY8$KDO%ZQN^LGW%U8T+OEO9!&L[3.8FR
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M,C R-3 R,C1X97@S9#$N:'1M4$L! A0#%     @ +7!86MKM+NLD#@  USL
M !8              ( !&SP  &%E;VXM,C R-3 R,C1X97@Y.2YH=&U02P4&
2      < !P#3 0  <TH

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>aeon-20250224x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aeon-20250224.xsd" xlink:type="simple"/>
    <context id="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837607</identifier>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_d4URmFxzd0CW7KBq7rTIyg_2_1">0001837607</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_JvA4Xv-c20-urp5JrcZchw_3_1">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_Th76yLB1tE-atk6m6_2BFA_4_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_luq_sqoW8UK-YKSylB2USw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_bOHZwPT040iTVr6oTonuMQ">2025-02-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_YUFzgb_03EqMz88y1nzE9g">AEON Biopharma,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_pdtfa48Yv02OZByPVadCtg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_lv7skw-AZUmkSFknN3nuyQ_1_2">001-40021</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_NyZV33p9PkSzA3pdYpUqoQ_1_4">85-3940478</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_W721m699oUWx6g91P9-U7g">5 Park Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_94hTkhqBGEaASVJZB3-hQw">Suite&#160;1750</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_VtwN53k6BUO55IEJamtW2A">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_WgV_JsjS00q5Z2uvCFNLhg">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_ecAsPVfPE0SNWN1ycH7zUw">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_3glHtr-NbECZPQ9Gp67okw">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_Jd1HSGU8WUeQx6DD8in0sQ">354-6499</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_G5zoCP8ZeEqXPqm20X-LPA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_RY29oCgDlEaPP21FzOujbw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_XYSKmgJrREu2UFnAC0ydxA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_lIXo2yR9jEiMJZx2UTJ-Jg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_TmKBrq7_WECXCy2gwyHTfQ_2_0">Class&#160;A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_WkVfeh34WkSBcBamLNoHug_2_2">AEON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Tc_SH2yYDCZdkGDxBUVjEE5wQ_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_pFJEJDnzZU-XRMWb8KW-6Q">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_2_24_2025_To_2_24_2025_HPSQShBh2UW-pXj-QzBw5w"
      id="Narr_vnJLtn9weUmC6f13T3yd4A">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
